Current Size: 100%

News

Richard Moriggl receives prestigious Austrian cancer research award

Richard Moriggl, director of the LBI-CR

This year Richard Moriggl was selected for the "Große Zentraleuropäische Preis"  for cancer research to mark his excellent scientific achievements in the field with the development of clinically relevant cancer models. His research proves to be of international relevance since many years. In the name of the entire board Univ.-Prof. Dr. Ehalt congratulated Richard Moriggl to his succesful research.

Jan Pencik receives poster prize at first LBG health sciences meeting

The LBG organised a special meeting for all Ludwig Boltzmann Institutes and Clusters, active in the area of medicine and life sciences as well as its related disciplines. The main purpose was to get to know each other’s research, to establish new cooperations under the roof of the LBG and to inform the medical community/public about the health related LBG activities. The common denominator of the participating institutes and clusters is also the namesake of the meeting: Health Sciences

Dr. Moriggl thanks DI Pröll and BM Töchterle for their support

At the recent networking event of the LBG, held on the twentieth floor of the Raiffeisenhaus in Vienna, Dr. Moriggl presented science minister Karlheinz Töchterle and President Josef Pröll with a collection of scientific images. He used the opportunity to show his gratitude to both for their support in extending the LBI-CR for a second funding period and discussed his future plans to maintain momentum for the research institute.

Secret second life of cdk6 in lymphomas

CDK6 is an oncogenic kinase regulating the cell cycle. In CancerCell a research team led by Prof. Veronika Sexl from the Veterinary University Vienna and contributions from the LBI-CR demonstrated that CDK6 performs a kinase-independent transcriptional function in regulating expression of VEGF-Aandp16 INK4a.These observations link the cell cycle machinery and angiogenesis and reveal the presence of a fail-safe antiproliferative mechanism.
 

Alternative target for breast cancer drugs

Scientists from the Ludwig Boltzmann Institut for Cancer Research have contributed to identify higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new drug target for the treatment of breast cancer. The results, which are published in EMBO Molecular Medicine, show that elevated levels of the protein Ret, which is short for “Rearranged during transfection”, are associated with a lower likelihood of survival for breast cancer patients in the years following surgery to remove tumours and cancerous tissue.

Pages